|
Market Closed -
Nasdaq Helsinki
19:00:00 19/08/2026 +03
|
5-day change | 1st Jan Change | ||
| 79.10 EUR | +0.96% |
|
+1.48% | +24.27% |
| 08-10 | Orion License Partner Tenax's Pulmonary Hypertension Drug Fails to Improve Walk Distance in Late-stage Trial | MT |
| 08-10 | Orion partner's phase 3 study with levosimendan missed its goals | FW |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
EBIT - Evolution of Analysts' Estimates
Dividend / Share (DPS) - Evolution of Analysts' Estimates
Cash or Net Debt - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
EBIT
Dividend / Share (DPS)
Cash or Net Debt
- Stock Market
- Stocks
- ORNBV Stock
- Consensus Orion Oyj
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
